Show simple item record

dc.contributor.authorAgrawal, Utkarsh
dc.contributor.authorBedston, Stuart
dc.contributor.authorMcCowan, Colin
dc.contributor.authorOke, Jason
dc.contributor.authorPatterson, Lynsey
dc.contributor.authorRobertson, Chris
dc.contributor.authorAkbari, Ashley
dc.contributor.authorAzcoaga-Lorenzo, Amaya
dc.contributor.authorBradley, Declan T
dc.contributor.authorFagbamigbe, Adeniyi Francis
dc.contributor.authorGrange, Zoe
dc.contributor.authorHall, Elliott C R
dc.contributor.authorJoy, Mark
dc.contributor.authorKatikireddi, Srinivasa Vittal
dc.contributor.authorKerr, Steven
dc.contributor.authorRitchie, Lewis
dc.contributor.authorMurphy, Siobhán
dc.contributor.authorOwen, Rhiannon K
dc.contributor.authorRudan, Igor
dc.contributor.authorShah, Syed Ahmar
dc.contributor.authorSimpson, Colin R
dc.contributor.authorTorabi, Fatemeh
dc.contributor.authorTsang, Ruby S M
dc.contributor.authorde Lusignan, Simon
dc.contributor.authorLyons, Ronan A
dc.contributor.authorO'Reilly, Dermot
dc.contributor.authorSheikh, Aziz
dc.date.accessioned2022-10-14T15:50:01Z
dc.date.available2022-10-14T15:50:01Z
dc.date.issued2022-10-15
dc.identifier.citationAgrawal , U , Bedston , S , McCowan , C , Oke , J , Patterson , L , Robertson , C , Akbari , A , Azcoaga-Lorenzo , A , Bradley , D T , Fagbamigbe , A F , Grange , Z , Hall , E C R , Joy , M , Katikireddi , S V , Kerr , S , Ritchie , L , Murphy , S , Owen , R K , Rudan , I , Shah , S A , Simpson , C R , Torabi , F , Tsang , R S M , de Lusignan , S , Lyons , R A , O'Reilly , D & Sheikh , A 2022 , ' Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters : pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales ' , The Lancet , vol. 400 , no. 10360 , pp. 1305-1320 . https://doi.org/10.1016/S0140-6736(22)01656-7en
dc.identifier.issn0140-6736
dc.identifier.otherPURE: 219977811
dc.identifier.otherPURE UUID: ac2962d8-baae-4cd7-a652-4e034013fb35
dc.identifier.otherRIS: urn:874F838E134EC9EB6DEA28C54FC93968
dc.identifier.urihttps://hdl.handle.net/2164/19379
dc.descriptionThis work was funded by the National Core Studies–Immunity group. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20060), with support from the DaC-VaP-2 study also funded by UK Research and Innovation (grant ref MC_PC_20058). The study entitled “Use of national linked health care, serological data, and viral genomic data to identify and characterise post-third and -booster dose vaccine breakthroughs at a population level” is a partnership between the University of Edinburgh, Swansea University, Oxford University, Queen’s University of Belfast, University of St Andrews, and The Office for National Statistics. The authors would like to acknowledge all other project collaborators not involved in these analyses but who are contributing to wider discussions and preceding outputs. EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE–The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and is delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government Director-General Health and Social Care.en
dc.format.extent16
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.rights© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/R008345/1en
dc.subjectUK Research and Innovation (UKRI)en
dc.subjectMC_PC_20060en
dc.subjectMC_PC_20058en
dc.subjectMC_PC_19004en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleSevere COVID-19 outcomes after full vaccination of primary schedule and initial boosters : pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Walesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Educationen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(22)01656-7
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0140673622016567en
dc.identifier.vol400en
dc.identifier.iss10360en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record